Member Info for thebamf

Not currently invested here but to my mind NCYT is starting to look seriously oversold, I'm in some other covid stocks but to me NCYT remains the best indicator of where this fledgling industry is heading. NCYT may not have the most advance tech but they are doing a great job of defending their market with mobile test kits on the way. All looks good here and I've no doubt you'll be moving up from here, I will def be buying at these levels when funds allow. Gl to holders

No one here should be giving you advice, always DYOR. Personally putting all of your savings in one share I would see as a very high risk strategy, I favor being invested in multiple shares which reduces my risk (but also reward) in any one stock.

Only you know your own financial situation and appetite for risk so you will have to make your own decisions accordingly.

That said, hoping for a big week here, good luck to all holders.

I've held here off and on for years, thankfully just punt money, it's been a bit like holding a lottery ticket where the prize is reduced every week and then your numbers still don't come up. Years of waiting for a farm in/out deal expecting it to be a major player then turned out to be PMO, a relative minnow now they don't even want it.

We now face industry wide over supply of oil while countries like Saudi sell off their oil assets to invest in renewable's. No one was interested in this "asset" before what appetite will there be for it now?

Now look at the share price getting ever closer to 0.00, soon a consolidation will be on its way at 10 or 100 to one before the sp resumes its terminal decline with more inevitable placings.

The real bad news is that at a 20mil mcap we are not even appealing to traders wanting a quick pump and dump so no reason to average down in the hope of getting out on a spike.

My holding here is now firmly in the bottom draw marked "lessons learned" and I will not be averaging down, there are much better prospects around at the moment. If this company ever manages to earn any cash that isn't rinsed from their share holders, I'm sure there will be ample opportunity to buy into it at a lower price than today, next month or next year.

IMO obvs.

I for one will assume this is genuine and say thanks for your efforts and keep up the great work :)

NT to buy, MM's on the rob.

https://twitter.com/vreducation

Looks good, will have to sit in on a few. Just been looking at the Twitter feed too, looks like we're hiring. Check out the fireman simulator too if you've not seen it. Really shows the potential of VR for training, amazing stuff.

Big drop because we hit the physiological 30p mark, people expect it so sell into it and it becomes self fulfilling prophecy, I'm in another recovery stock on the same trajectory that hit 30p at the same time as AA. back now to the 25ish like these. Hopefully we'll hold this base and make another attack on 30p in the next week or so. Fundamentals are good, trend is up.

The week before AVCT announced there contract with Cytiva there was a spike in volume with massive buys vs sells. So could be an indicator that a significant RNS is on the way. Especially if we see more of the same.

Sold 17k Bought 1m hmm. Without wanting to sound to rampy but the last time I saw a difference that big was when AVCT were at 20p. Will be keeping a close eye on this, this week.

Who knows where BTC or ARB will be by end of day, but we know at these levels we'll remain well profitable and it's likely that BTC will kick on from here so all good. A day for crypto fans to celebrate as BTC continues to defy the naysayers.

Only found out about VRE over the weekend and really liking what I see so far. The experience revenues alone look set to more than justify our Mcap. With the partner list and Engage platform falling into place I've no doubt things are going to get exciting here. Started looking to buy an all in one Oculas quest, waiting list until end of June so looks like mass VR adoption is well underway.

I was very happy with the price I got here on Wednesday and think we've already seen the bottom here, if people held through the lows of March I don't think your faith will be tested further. Covid 19 is the biggest economic catalyst we will see in our lifetimes and green tech is going to be a major beneficiary. Obviously the big focus is on biotech at the moment but I've seen enough news articles on "How good smog free cities look during lockdown" and how "Humanity is facing a bigger crisis" already to know where the news flow is going in a few months time. The Energy Superhub in Oxford is going to get attention, a lot of attention and when it does it will start a nationwide effort to make Britain green.

Lots of people will be out of work following the immediate fallout from covid and only massive infrastructure projects will save us. Cities will be in a race to become green throughout Britain and around the world as the price of vanadium goes up faster than we can get it out the ground, all imo obviously. I hope it happens soon for anyone seriously down on their investment.

@Cheapsharesboy I'm sure we're going much higher, but always a good strategy to de-risk then go and seed your next investment imo. I'll be doing the same when we hit 40 here.

MM's loading up.

The upfront payment for this alone is likely to be more than the £18mil loss so relax, the reason the loss seems so high is because the revenue is about to go into orbit:

Moderna Therapeutics Inc exercised its option to enter into an exclusive licensing agreement for Affimers against an undisclosed target; part of an ongoing research collaboration between the two companies. A future regulatory submission by Moderna for an Affimer clinical candidate would trigger the next milestone payment to Avacta.

Normal service has been resumed.

The POC test will uses GDR's own machine, the machine they've just had a million quids worth of orders from the US Department of Defence for - Draw your own conclusions.

I should clarify
only this was taken direct from RNS:

"On 24 April 2020, genedrive announced that it had entered into a distribution agreement with Inspiration Healthcare Group plc for the distribution of genedrive's AIHL test in the UK and Ireland. The Directors estimate the UK and global markets for this test to be worth up to £3.5 million and £35 million per year, respectively, to genedrive based on a price of £2,000 per Genedrive® unit and £35 per test."

From the RNS:

"On 24 April 2020, genedrive announced that it had entered into a distribution agreement with Inspiration Healthcare Group plc for the distribution of genedrive's AIHL test in the UK and Ireland. The Directors estimate the UK and global markets for this test to be worth up to £3.5 million and £35 million per year, respectively, to genedrive based on a price of £2,000 per Genedrive® unit and £35 per test."

This test is estimated to save the NHS £5mil a year.

It's worth mentioning that this test was a proof of concept for GDR, they expect to be able to apply the tech to many other tests. The tests are used to identify people who may experience severe or lasting side effects from certain drugs.